243 related articles for article (PubMed ID: 34511903)
1. Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects.
Xie S; Hou X; Yang W; Shi W; Yang X; Duan S; Mo F; Liu A; Wang W; Lu X
Int J Nanomedicine; 2021; 16():6017-6034. PubMed ID: 34511903
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers.
Yang X; Zhao J; Duan S; Hou X; Li X; Hu Z; Tang Z; Mo F; Lu X
Theranostics; 2019; 9(14):4066-4083. PubMed ID: 31281532
[No Abstract] [Full Text] [Related]
3. A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine.
Shi W; Yang X; Xie S; Zhong D; Lin X; Ding Z; Duan S; Mo F; Liu A; Yin S; Jiang X; Xu ZPG; Lu X
Cancer Lett; 2021 Dec; 522():184-197. PubMed ID: 34562519
[TBL] [Abstract][Full Text] [Related]
4. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
5. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
[No Abstract] [Full Text] [Related]
6. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L; Simon S; Vignard V; Dupre E; Gantier M; Cruard J; Alberge JB; Hussong M; Deleine C; Heslan JM; Shaffer J; Beauvais T; Gaschet J; Scotet E; Fradin D; Jarry A; Nguyen T; Labarriere N
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 32001504
[TBL] [Abstract][Full Text] [Related]
7. Generation of Cancer-Specific Cytotoxic PD-1
Lu S; Yang N; He J; Gong W; Lai Z; Xie L; Tao L; Xu C; Wang H; Zhang G; Cao H; Zhou C; Zhong L; Zhao Y
J Biomed Nanotechnol; 2019 Mar; 15(3):593-601. PubMed ID: 31165703
[TBL] [Abstract][Full Text] [Related]
8. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
9. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.
Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066
[TBL] [Abstract][Full Text] [Related]
10. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
11. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
12. PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth.
Kwak SY; Lee S; Han HD; Chang S; Kim KP; Ahn HJ
Mol Pharm; 2019 Dec; 16(12):4940-4953. PubMed ID: 31651174
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
14. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
[TBL] [Abstract][Full Text] [Related]
15. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
[TBL] [Abstract][Full Text] [Related]
16. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
17. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
[TBL] [Abstract][Full Text] [Related]
18. CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes.
Shi L; Meng T; Zhao Z; Han J; Zhang W; Gao F; Cai J
Gene; 2017 Dec; 636():36-41. PubMed ID: 28888577
[TBL] [Abstract][Full Text] [Related]
19. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
20. CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes.
Zhao Z; Shi L; Zhang W; Han J; Zhang S; Fu Z; Cai J
Oncotarget; 2018 Jan; 9(4):5208-5215. PubMed ID: 29435173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
